RALIOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
$0M01FY2000RRNIH
University Of Chicago, Chicago IL
Investigators
Linked publications & trials
Paper 33788946Paper 32889963Paper 30535721Paper 27459230Paper 27210268Paper 25885822Paper 25840648Paper 25544740Paper 25411163Paper 24882155Paper 24823702Paper 24732925Paper 24588711Paper 24285773Paper 23986859Paper 23913942Paper 23806029Paper 23633200Paper 23576237Paper 23553855Paper 23447518Paper 23308388Paper 22986150Paper 22867037Paper 22847947Paper 22763622Paper 22763267Paper 22544009Paper 22541936Paper 22101912Paper 21798578Paper 21671531Paper 21632481Paper 21530736Paper 21426455Paper 21112019Paper 21050867Paper 20816944Paper 20798258Paper 20624651Paper 20553679Paper 20414144Paper 20332249Paper 20176450Paper 20150301Paper 20100807Paper 20091113Paper 20070572Paper 19968402Paper 19955752Paper 19910025Paper 19837518Paper 19782423Paper 19773379Paper 19756530Paper 19657584Paper 19646680Paper 19595703Paper 19567526Paper 19444258Paper 19302083Paper 19255602Paper 19240158Paper 19240152Paper 19133287Paper 19124843Paper 19056602Paper 19026577Paper 18936915Paper 18925859Paper 18839415Paper 18770076Paper 18719052Paper 18702049Paper 18655531Paper 18650797Paper 18647805Paper 18622306Paper 18606653Paper 18591489Paper 18581219Paper 18577985Paper 18521921Paper 18516218Paper 18403759Paper 18346991Paper 18245794Paper 18179313Paper 18172212Paper 18158263Paper 17961988Paper 17932107Paper 17901983Paper 17560739Paper 17552955Paper 17520786Paper 17477941Paper 17442599Paper 17308390Paper 17264335
Abstract
To establish the long-term effects of raloxifene, a phase III, multi-center, double-blind, placebo-controlled, randomized trial at two doses (60 or 120 mg) will be conducted in 36 postmenopausal women with low bone mineral density or thoracic or lumbar vertebral compression fracture. The primary endpoint is that rate of vertebral fractures in raloxifene-treated vs. placebo controls.
View original record on NIH RePORTER →